MSL
BCRX icon

Mackay Shields LLC’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mackay Shields LLC’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,508
Closed -$402K – 775
2021
Q1 		$402K Buy
+39,508
New +$407K ﹤0.01% 1257

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Mackay Shields LLC's BCRX Position: Q2 2021 in Review

Mackay Shields LLC sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 39,508 shares — an estimated $402K sold.

Mackay Shields LLC first reported a position in BCRX in Q1 2021 and held it in 1 quarter. The position peaked at $402K in Q1 2021. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Mackay Shields LLC reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 39,508 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $402K.
  • Mackay Shields LLC first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Mackay Shields LLC's BioCryst Pharmaceuticals position peaked at $402K in Q1 2021.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.